TSX: ACB | NYSE: ACB
Provides Flexibility to Execute on Aurora's
Global Expansion and Partnering Strategy
EDMONTON, April 2, 2019 /PRNewswire/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today
that it has filed a preliminary short form base shelf prospectus
(the "Shelf Prospectus") with the securities regulators in each
province of Canada, except for the
Province of Quebec, and a
corresponding shelf registration statement on Form Fâ10 (the
"Registration Statement") with the United States Securities and
Exchange Commission (the "SEC").
"Although we have no immediate intention of drawing capital
against this Shelf Prospectus, we have introduced this option as a
prudent and long-term strategic measure to provide us with
flexibility in access to growth capital, if or when required, to
continue executing on our global expansion and partnering
strategy," said Michael Singer,
Executive Chairman. "With our recent listing on the NYSE, our
successful financing in January 2019
led by U.S. institutional investors, and as we work with
Nelson Peltz to explore potential
partnership opportunities, this filing is a natural evolution for
our company as we rapidly mature into a global and profitable
organization."
The Shelf Prospectus and Registration Statement, when made final
or effective, will allow the Company to make offerings of common
shares, debt securities, subscription receipts, units, warrants or
any combination thereof of up to US$750
million during the 25 month period that the Shelf Prospectus
is effective. Should the Company decide to offer securities during
this period, the specific terms, including the use of
proceeds from any offering, will be set forth in a related
prospectus supplement to the Shelf Prospectus, which will be filed
with the applicable Canadian securities regulatory authorities and
the SEC.
The Company is also considering the use of the Shelf Prospectus
and subsequent prospectus supplement to allow for an "at the market
distribution" in accordance with applicable securities laws.
An at-the-market distribution provides for securities to be sold by
registered dealers on behalf of the Company through the stock
exchange at prevailing market prices at the time of sale.
Currently, no agreement has been entered into for an at-the-market
distribution.
A copy of the Shelf Prospectus can be found on SEDAR at
www.sedar.com and a copy of the Registration Statement can be found
on EDGAR at www.sec.gov.
The Registration Statement has been filed with the SEC but has
not yet become effective. No securities may be sold nor may offers
to buy be accepted prior to the time the Registration Statement
becomes effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any jurisdiction in which an offer,
solicitation or sale would be unlawful prior to registration or
qualifications under the securities laws of any such
jurisdiction.
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 500,000 kg per
annum and sales and operations in 24 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high quality product at low cost. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet EU GMP standards, and its
first production facility, the recently acquired MedReleaf Markham
facility, and its wholly owned European medical cannabis
distributor Aurora Deutschland have achieved this level of
certification.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 16 wholly
owned subsidiary companies â MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela,
ICC Labs and Whistler â Aurora is distinguished by its reputation
as a partner and employer of choice in the global cannabis sector,
having invested in and established strategic partnerships with a
range of leading innovators, including: Radient Technologies Inc.
(TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group
Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom
Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty
Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC:
CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc. (CSE:HITI).
Aurora's Common Shares trade on the NYSE and TSX under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur and include, but are not to, statements
regarding the filing and effectiveness of the final Shelf
Prospectus and Registration Statement, the filing and effectiveness
of any potential prospectus supplement; the amount and terms of any
securities to be offered, and anticipated timing of any financing
under the final Shelf Prospectus and Registration Statement. These
statements are only predictions. Various assumptions were used in
drawing the conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. including but
not limited to, the timing and filing of the final Shelf
Prospectus; the potential offering of any securities by the
Company; uncertainty with respect to the completion of any future
offering; the ability to obtain applicable regulatory approval for
any contemplated offerings; the ability of the Company to negotiate
and complete future funding transactions, as well as the risks
identified under the heading Risk Factors in our Annual Information
Form for the fiscal year ended June
30, 2018. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX nor its Regulation Services Provider (as that term
is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-files-preliminary-base-shelf-prospectus-300823511.html
SOURCE Aurora Cannabis Inc.